Capital Advisors Inc. OK Raises Position in Johnson & Johnson $JNJ

Capital Advisors Inc. OK lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 11.2% in the 2nd quarter, HoldingsChannel reports. The firm owned 25,520 shares of the company’s stock after buying an additional 2,562 shares during the quarter. Capital Advisors Inc. OK’s holdings in Johnson & Johnson were worth $3,898,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of JNJ. Nuveen LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $1,369,188,000. Bank of New York Mellon Corp grew its stake in Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Pacer Advisors Inc. grew its stake in Johnson & Johnson by 1,382.0% in the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock valued at $502,509,000 after buying an additional 2,825,626 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Johnson & Johnson by 159.6% in the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock valued at $635,327,000 after buying an additional 2,557,388 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC purchased a new position in Johnson & Johnson in the 2nd quarter valued at approximately $401,420,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.4%

Shares of NYSE:JNJ opened at $188.95 on Wednesday. Johnson & Johnson has a one year low of $140.68 and a one year high of $189.92. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market cap of $455.06 billion, a price-to-earnings ratio of 20.21, a PEG ratio of 2.40 and a beta of 0.40. The firm has a fifty day moving average price of $177.04 and a two-hundred day moving average price of $163.18.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the previous year, the firm posted $2.82 EPS. The firm’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. Citigroup lifted their price objective on shares of Johnson & Johnson from $200.00 to $213.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Johnson & Johnson in a research note on Saturday, September 27th. JPMorgan Chase & Co. lifted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Royal Bank Of Canada raised their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Finally, Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $189.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.